Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Abiraterone in patients with recurrent epithelial ovarian cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.10.16
Views: 1677

Dr Susanna Banerjee - The Royal Marsden, London, UK

Dr Banerjee speaks with ecancertv at ESMO 2016 about the primary results from the CORAL trial.

She outlines the background of anti-androgen therapy which has led to abiraterone, a CIP17 upstream inhibitor of androgen and oestrogen, and considers other avenues of research that may help patients with advanced ovarian cancer.

Dr Banerjee explains that, while 26% of patients in the trial had a clinical benefit and 14% a prolonged benefit, only 1 patient of the cohort of 42 was fully responsive, leading to cessation of the study.

With these results in mind, she believes that further understanding of highly responsive patient subtypes will help in advancing ovarian cancer care for all patients.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation